# EDGAR Filing Document

**Accession Number:** 0001798749
**File Stem:** 0001193125-26-221557
**Filing Date:** 2026-5
**Character Count:** 2528
**Document Hash:** 7c44579b2d15f19f302603708f4a17e9
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-221557.hdr.sgml**: 20260616

**ACCESSION NUMBER**: 0001193125-26-221557

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260513

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Jade Biosciences, Inc.
- **CENTRAL INDEX KEY:** 0001798749
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 831377888
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 221 CRESCENT ST.
- **STREET 2:** BUILDING 23, SUITE 105
- **CITY:** WALTHAM
- **STATE:** MA
- **ZIP:** 02453
- **BUSINESS PHONE:** (781) 312-3013

**MAIL ADDRESS:**
- **STREET 1:** 221 CRESCENT ST.
- **STREET 2:** BUILDING 23, SUITE 105
- **CITY:** WALTHAM
- **STATE:** MA
- **ZIP:** 02453

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Aerovate Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20200103

**Jade Biosciences, Inc.** 

**221 Crescent St., Building 23, Suite 105** 

**Waltham, MA 02453** 

May 13, 2026

**<u>VIA EDGAR</u>**

Daniel Crawford

Office of Life Sciences

Division of Corporation Finance

U.S. Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

---

| | |
|:---|:---|
| **Re:** | **Jade Biosciences, Inc.**  |

---

**Registration Statement on Form S-3** 

**File No. 333-295662** 

To the addressee set forth above:

Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, the undersigned, on behalf of Jade Biosciences, Inc., respectfully requests that the effective date of the Registration Statement on Form S-3 referred to above be accelerated so that it will become effective at 4:00 P.M. Eastern Time on May 15, 2026, or as soon as practicable thereafter.

If you have any questions or require additional information, please contact Anthony Gostanian of Latham & Watkins LLP at (858) 523-3969. Thank you for your assistance and cooperation in this matter.

---

| | |
|:---|:---|
| Sincerely, | Sincerely, |
| JADE BIOSCIENCES, INC. | JADE BIOSCIENCES, INC. |
| By: | /s/ Elizabeth Balta |
|  | Elizabeth Balta |
|  | Chief Legal Officer and Corporate Secretary |

---

cc: Tom Frohlich, *Jade Biosciences, Inc.*

Bradford Dahms, *Jade Biosciences, Inc.*

Cheston Larson, *Latham & Watkins LLP*

Matthew T. Bush, *Latham & Watkins LLP*

Anthony Gostanian, *Latham & Watkins LLP*